Author:
Blommestein Hedwig M.,Armstrong Nigel,Ryder Steve,Deshpande Sohan,Worthy Gill,Noake Caro,Riemsma Rob,Kleijnen Jos,Severens Johan L.,Al Maiwenn J.
Funder
Health Technology Assessment Programme (GB)
Publisher
Springer Science and Business Media LLC
Subject
Public Health, Environmental and Occupational Health,Health Policy,Pharmacology
Reference24 articles.
1. Guide to single technology appraisal process. London: NICE; 2009. Available at: http://www.nice.org.uk/Media/Default/About/what-we-do/NICE-guidance/NICE-technology-appraisals/Guide-to-the-single-technology-appraisal-process.pdf . Accessed 30 March 2015.
2. Myelodysplastic syndrome (deletion 5q)—lenalidomide [ID480]. Available at: http://guidance.nice.org.uk/TAG/291 . Accessed 30 March 2015.
3. Wade R, Duarte A, Simmonds M, Rodriguez-Lopez R, Duffy S, Woolacott N, et al. The clinical and cost effectiveness of aflibercept in combination with irinotecan and fluorouracil-based therapy (FOLFIRI) for the treatment of metastatic colorectal cancer which has progressed following prior oxaliplatin-based chemotherapy: a critique of the evidence. Pharmacoeconomics. 2015;33(5):457–66.
4. Stevenson M, Pandor A, Stevens JW, Rawdin A, Rice P, Thompson J, et al. Nalmefene for reducing alcohol consumption in people with alcohol dependence: an Evidence Review Group perspective of a nice single technology appraisal. Pharmacoeconomics. 2015;33(8):833–847.
5. Holmes M, Davis S, Simpson E. Alteplase for the treatment of acute ischaemic stroke: a NICE single technology appraisal. An Evidence Review Group perspective. Pharmacoeconomics. 2015;33(3):225–33.
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献